Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies using functional genomics in rheumatic diseases.

Gerd R Burmester1, Thomas Häupl

  • 1Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Humboldt University and Free University of Berlin, Schumannstr. 20-21, 10098 Berlin, Germany. gerd.burmester@charite.de

Autoimmunity Reviews
|November 18, 2004
PubMed
Summary

Rheumatic diseases provide a unique model for studying chronic inflammation and autoimmunity, driven by both genetic factors and infection. Understanding their genetic basis is crucial for developing targeted therapies for these impactful inflammatory disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial.

Annals of the rheumatic diseases·2026
Same author

Introducing EULAR Rheumatology Open (ERO): A New Platform for Advancing Rheumatology Research.

EULAR rheumatology open·2026
Same author

Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study.

EULAR rheumatology open·2026
Same author

Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study.

EULAR rheumatology open·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.

Annals of the rheumatic diseases·2026

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Rheumatic diseases represent a significant public health challenge due to their frequency and socio-economic impact.
  • They offer a unique window into the progression from infection to chronic inflammation, autoimmunity, and immunopathology.
  • Well-characterized patient cohorts and accessible tissues facilitate molecular and genetic analyses.

Purpose of the Study:

  • To highlight the value of rheumatic diseases as a model for functional genomics in inflammatory disorders.
  • To emphasize the need for identifying genetic factors contributing to rheumatic disease pathogenesis.
  • To advocate for developing novel, genetically informed therapies for chronic inflammatory conditions.

Main Methods:

  • Analysis of patient cohorts with inflammatory rheumatic diseases.

Related Experiment Videos

  • Investigation of genetic predisposition and infectious triggers.
  • Molecular and cellular analysis of affected tissues.

    • Main Results:

    • Rheumatic diseases involve complex interactions between genetic susceptibility and infection.
    • Numerous genes likely contribute to disease risk and severity, though few are currently identified.
    • Functional genetic understanding is essential for personalized therapeutic strategies.

    Conclusions:

    • Gene analysis in inflammatory rheumatic diseases is vital for patient benefit and understanding broader inflammatory processes.
    • This research can lead to improved diagnostic and therapeutic strategies for rheumatic and other inflammatory disorders.
    • Further investigation into genetic factors will advance personalized medicine in rheumatology.